Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Inventiva Revises Phase III NASH Plans For Broader Indication

05 Jan 2023

• By Joseph Haas

Change of plans — Inventiva's revised Phase III NASH plans involve testing drug in cirrhotic patients • Source: Shutterstock

Related Content

NASH Drug Development Questions? US FDA Has Many Of The Answers

12 Feb 2021

Madrigal Phase III Success In NASH Spurs Buyout Speculation

19 Dec 2022

Year Of NASH Upheaval Means Incremental Data At AASLD

18 Nov 2020

Inventiva Moves Up In NASH, Hitting Multiple Phase IIb Endpoints

17 Jun 2020

RESOLVE-IT Failure Dashes Genfit's NASH Hopes

12 May 2020

Akero’s Phase II Success Could Augur Brighter Days For NASH R&D

16 Sep 2022

Related Companies

Inventiva S.A.

Genfit SA

Akero Therapeutics, Inc.

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.